Report Overview

Global Protease Inhibitors Market Size – Industry Trends & Forecast Report 2026

The global protease inhibitors market has reached USD XX Million in 2019 and is further projected to reach USD XX Million by 2026, growing at a CAGR of XX% during the forecast period. The primary factor for the growth of the protease inhibitors market can be attributed to the increasing prevalence of diseases such as HIV and HCV. Extensive research and development activities in the field of HIV treatment using protease inhibitors coupled with the rising awareness of antiretroviral therapy are expected to boost the protease inhibitors market growth.

Source: BlueWeave Consulting

Global Protease Inhibitors Market Overview:

The ‘protease inhibitor’ are molecules that have many different applications. In some cases, the ‘protease inhibitor’ (PI) indicates a type of drug that is primarily used to treat hepatitis and HIV/AIDS. Proteases are enzymes that cleave or cut proteins. Protease inhibitor inhibits the function of protease, thereby preventing viral replication. Inhibitors also block the proteolytic cleavage of the precursor protein required to produce new virus particles. These protease inhibitor drugs, apart from antiviral drugs, can be used in the treatment of cancer and diabetes. Several protease inhibitors can be used as reagents in protein purification or cell/tissue extraction.

Global Protease Inhibitors Market Forecast and Trends

Growth Drivers 

Increasing appeal of a protease inhibitor to boost the market growth

Protease inhibitors are being used in various fields nowadays. They are used in research for clinical application, drugs for the treatment of diseases such as HIV/AIDS and Hepatitis C, and others. The development of pharmaceutical protease inhibitors is of great interest which targets the specific protease enzyme (for example, in HIV anti-retroviral drugs). Thus, the increasing prevalence of viral diseases such as HIV/AIDS and hepatitis C is expected to drive the protease inhibitors market during the forecast period. On the back of this increasing product appeal, antiretroviral protease inhibitors are anticipated to fuel the protease inhibitors' market growth in the forecast period.

High prevalence of HIV and HCV to drive market growth

Antiretroviral protease inhibitors are major drugs in the treatment of diseases such as HIV and HCV. With the increasing number of cases coupled with a high prevalence of these diseases the demand for these drugs is bound to increase as well. The rising awareness about anti-retroviral therapy and cancer treatment is another major factor contributing to the growth of the global protease inhibitors market. Thereby, it is anticipated that the market for antiretroviral protease inhibitors will show significant CAGR over the forecast period.

Restraints

Stringent regulation environment coupled with side effects of a drug to hamper the growth

To protect the public from harmful drug effects, governments make rules and regulations stringent. Usually, government regulations make product development more expensive. Such an environment can create a hindrance in the market growth in that region. While Antiretroviral protease inhibitors have side effects and unbearable toxicity and hence people hesitate in using these drugs. So, there is a challenge in front of drug manufacturing companies to innovate and prepare drug which has either no side effects or they have only a few non-severe side effects.

Impact of COVID-19 in the industry

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations travel bans and quarantines restaurants closed all indoor events restricted over forty countries state of emergency declared massive slowing of the IT Spending market volatility falling business confidence, growing panic among the population, and uncertainty about future. The growth in the global protease inhibitors market is anticipated to be driven by the increased research for clinical application of protease inhibitors combined with the rise in demand for protease inhibitors in COVID-19. 

Global Protease Inhibitors Market: By Mechanism of action

Based on the mechanism of action, the global market can be divided into serine protease inhibitors, cysteine protease inhibitors, aminopeptidase inhibitors, aspartic protease inhibitors, metalloprotease inhibitors, and others. The serine protease inhibitor segment leads to the protease inhibitors market. It is anticipated to drive the growth for antiretroviral drugs in the protease inhibitors market on the back of its effectiveness in the treatment. Serine protease inhibitor forms a proteolytically inactive stoichiometric complex with the Serpins proteases which will play a vital role in the regulation of blood coagulation, complement activation, generation of kinins, and fibrinolysis. 

Source: BlueWeave Consulting

Global Protease Inhibitors Market: By Application

Based on application, the global protease inhibitors market has been divided into commodity protease inhibitor, research tool protease inhibitor, and protease inhibitor drugs. The protease inhibitor drugs segment is expected to hold a significant share of the global market from 2021 to 2026, due to the high prevalence of anti-retroviral diseases across the world. Protease inhibitors are being used in various fields nowadays. They are used in research for clinical application, drugs for the treatment of diseases such as HIV/AIDS and Hepatitis C, and others. On the back of this increasing product appeal, antiretroviral protease inhibitors are anticipated to fuel the market growth in the forecast period.

Global Protease Inhibitors Market: By End-Use

Based on end-user, the global market has been divided into hospitals & diagnostic centers, pharmaceutical industries, and academic & research institutes. The hospital segment leads to the protease inhibitors market. 

Hospitals are expected to hold a significant share of the global market from 2021 to 2026, owing to the high prevalence of diseases such as HIV and HCV has increased the demand for drugs in hospitals. Moreover, with the increasing popularity of online pharmacies, the supply chain in the field of drug delivery is expected to improve tremendously.

Global Protease Inhibitors Market: Regional insights

The global Protease Inhibitors market is segmented into five regions including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The North American region is anticipated to dominate the global protease inhibitors market, during the forecast period owing to increasing cases of HIV and chronic HCV, growing industrial sector, and advanced health care infrastructure in the region. Asia Pacific region is expected to register the maximum CAGR during the forecast period, owing to factors such as rising health care expenditure and increasing focus of global pharmaceutical companies in the Asia Pacific region. A rise in awareness about antiretroviral diseases in the Asian and African regions will drive the growth of the market.

Competitive landscape

Key players for global protease inhibitors market includes: Thermo Fisher Scientific Inc., Sigma-Aldrich, Inc., CYTOSKELETON, INC., Merck & Co., Inc., Genentech, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Bristol-Myers Squibb Company, Janssen Pharmaceutical Companies, GlaxoSmithKline plc, Vertex Pharmaceuticals, CSL Behring LLC., Takeda Pharmaceutical Company Limited, Pharming Technologies B.V.,KalVista Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Ionis Pharmaceuticals, Inc., Centogene AG & Other prominent players.

In order to attain a competitive position in the global market, key players in the protease inhibitors market are engaged in mergers and acquisitions, extensive R&D activities, launch of cost-effective and efficient vaccine products, and collaborative partnerships.

Recent Development

• In April 2020: San Diego Supercomputer Center (SDSC) researchers reported that they have created a pharmacophore model and conducted data mining of the conformational database of FDA-approved drugs. These drugs are known to identify 64 compounds as potential inhibitors of the COVID-19 protease.

• In July 2018: Janssen Pharmaceuticals Company announced that it has received the FDA approval for its protease inhibitor class of drug, known as SYMTUZA, which is anticipated to be used for the treatment of HIV infection.

Scope of the Report

 By Mechanism of Action

• Serine protease inhibitors

• Cysteine protease inhibitors

• Amino peptidase inhibitor

• Aspartic protease inhibitors

• Metalloprotease inhibitors

• Others

By Application

• Commodity protease inhibitor

• Research tool protease inhibitor

• Protease inhibitor drugs

• Others

By End-Use

• Hospitals & diagnostic centers

• Pharmaceutical industries

• Academic

• Research institutes

By Region

• Asia Pacific

• North America

• Europe

• Middle East & Africa

• Latin America

1.     Research Framework

1.1.   Research Objective

1.2.   Product Overview

1.3.   Market Segmentation

2.     Research Methodology

2.1.   Qualitative Research

2.1.1.   Primary & Secondary Research

2.2.   Quantitative Research

2.3.   Market Breakdown & Data Triangulation

2.3.1.   Secondary Research

2.3.2.   Primary Research

2.4.   Breakdown of Primary Research Respondents, By Region

2.5.   Assumption & Limitation

3.     Executive Summary

4.     Global Protease Inhibitors Market Insights

4.1.   Industry Value Chain Analysis

4.2.   DROC Analysis

4.2.1.   Growth Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

4.2.4.   Challenges

4.3.   Recent Development

4.4.   Porter’s Five Forces Analysis

4.4.1.   Bargaining Power of Suppliers

4.4.2.   Bargaining Power of Buyers

4.4.3.   Threat of New Entrants

4.4.4.   Threat of Substitutes

4.4.5.   Intensity of Rivalry

4.5.   Impact of Covid-19 on Protease Inhibitors Industry

5.     Global Protease Inhibitors Market Overview

5.1.   Market Size & Forecast by Value, 2016-2026

5.1.1.   By Value (USD Million)

5.2.   Market Share & Forecast

5.2.1.   By Mechanism of action

5.2.1.1.       Serine protease inhibitors

5.2.1.2.       Cysteine protease inhibitors

5.2.1.3.       Amino peptidase inhibitor

5.2.1.4.       Aspartic protease inhibitors

5.2.1.5.       Metalloprotease inhibitors

5.2.1.6.       Others

5.2.2.   By Application

5.2.2.1.       Commodity protease inhibitor

5.2.2.2.       Research tool protease inhibitor

5.2.2.3.       Protease inhibitor drugs

5.2.2.4.       Others

5.2.3.   By End-User

5.2.3.1.       Hospitals & diagnostic centers

5.2.3.2.       Pharmaceutical industries

5.2.3.3.       Academic

5.2.3.4.       Research institutes  

5.2.4.   By Region

5.2.4.1.   North America

5.2.4.2.   Europe

5.2.4.3.   Asia Pacific

5.2.4.4.   Latin America

5.2.4.5.   Middle East & Africa

6.     North America Protease Inhibitors Market

6.1.   Market Size & Forecast by Value, 2016-2026

6.1.1.   By Value (USD Million)

6.2.   Market Share & Forecast

6.2.1.   By Mechanism of action

6.2.2.   By Application

6.2.3.   By End-User

6.2.4.   By Country

6.2.4.1.     United States

6.2.4.2.     Canada

7.     Europe Protease Inhibitors Market

7.1.   Market Size & Forecast by Value, 2016-2026

7.1.1.   By Value (USD Million)

7.2.   Market Share & Forecast

7.2.1.   By Mechanism of action

7.2.2.   By Application

7.2.3.   By End-User

7.2.4.   By Country

7.2.4.1.       Germany

7.2.4.2.       Italy

7.2.4.3.       France

7.2.4.4.       United Kingdom

7.2.4.5.       Spain

7.2.4.6.       Rest of Europe

8.     Asia Pacific Protease Inhibitors Market

8.1.   Market Size & Forecast by Value, 2016-2026

8.1.1.   By Value (USD Million)

8.2.   Market Share & Forecast

8.2.1.   By Mechanism of action

8.2.2.   By Application

8.2.3.   By End-User

8.2.4.   By Country

8.2.4.1.     China

8.2.4.2.     India

8.2.4.3.     Japan

8.2.4.4.     South Korea

8.2.4.5.     Rest of Asia Pacific

9.     Latin America Protease Inhibitors Market

9.1.   Market Size & Forecast by Value, 2016-2026

9.1.1.   By Value (USD Million)

9.2.   Market Share & Forecast

9.2.1.   By Mechanism of action

9.2.2.   By Application

9.2.3.   By End-User

9.2.4.   By Country

9.2.4.1.     Brazil

9.2.4.2.     Mexico

9.2.4.3.     Rest of Latin America

10.  Middle East & Africa Protease Inhibitors Market

10.1.  Market Size & Forecast by Value, 2016-2026

10.1.1.                  By Value (USD Million)

10.2. Market Share & Forecast

10.2.1.                  By Mechanism of action

10.2.2.                  By Application

10.2.3.                  By End-User

10.2.4.                  By Country

10.2.4.1.      Saudi Arabia

10.2.4.2.      Egypt

10.2.4.3.      Qatar

10.2.4.4.      UAE

10.2.4.5.      GCC

10.2.4.6.      Rest of Middle East & Africa

11.  Competitive Landscape

11.1.List of Key Players and Their Offerings

11.2.Market/Ranking Share Analysis

11.3.Competitive Benchmarking, By Operating Parameters

12.  Company Profile (Company Overview, Financial Matrix, Competitive landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

12.1. Thermo Fisher Scientific Inc.

12.2. Sigma-Aldrich, Inc.

12.3. CYTOSKELETON, INC.

12.4. Merck & Co., Inc.

12.5. Genentech, Inc.

12.6. Boehringer Ingelheim International GmbH

12.7. AbbVie Inc.

12.8. Bristol-Myers Squibb Company

12.9. Janssen Pharmaceutical Companies

12.10.            GlaxoSmithKline plc

12.11.            Vertex Pharmaceuticals

12.12.            CSL Behring LLC.

12.13.            Takeda Pharmaceutical Company Limited

12.14.            Pharming Technologies B.V.

12.15.            KalVista Pharmaceuticals, Inc

12.16.            BioCryst Pharmaceuticals

12.17.            Ionis Pharmaceuticals, Inc.

12.18.            Centogene AG

12.19.            Other prominent players